| 000 | 00957 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250513070351.0 | ||
| 264 | 0 | _c19940113 | |
| 008 | 199401s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/0002-9149(93)90040-j _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoden, D M | |
| 245 | 0 | 0 |
_aCurrent status of class III antiarrhythmic drug therapy. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cAug 1993 |
||
| 300 |
_a44B-49B p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aTorsades de Pointes _xchemically induced |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 72 _gno. 6 _gp. 44B-49B |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0002-9149(93)90040-j _zAvailable from publisher's website |
| 999 |
_c8256037 _d8256037 |
||